How many CCS- and ACS-patients might reach the newly recommended LDL-C-target <55mg/dl in clinical practice if guidelines were applied – an estimate from the DYSIS II study population
| العنوان: | How many CCS- and ACS-patients might reach the newly recommended LDL-C-target <55mg/dl in clinical practice if guidelines were applied – an estimate from the DYSIS II study population |
|---|---|
| المؤلفون: | Anselm K. Gitt, Ralf Zahn, Jean Ferrières, Dominik Lautsch, Martin Horack |
| المصدر: | European Heart Journal. 41 |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Fasting lipid profile, Myocardial ischemia, business.industry, Coronary arteriosclerosis, Clinical Practice, Internal medicine, medicine, ANTILIPEMIC AGENTS, Population study, LDL Cholesterol Lipoproteins, Cardiology and Cardiovascular Medicine, PCSK9 Inhibitors, business |
| الوصف: | Background The 2019 ESC guidelines for the management of dyslipidemia even further lowered the LDL-C-target values for the very high-risk population from Methods The Dyslipidemia International Study (DYSIS II) prospectively collected data of patients with chronic coronary syndromes (CCS) and acute coronary syndromes (ACS) (all on statins) in 18 countries in Europe, the Middle East, South- and East Asia to document patient characteristics, medication and a current lipid profile from 2012 to 2014 under real life conditions in physicians' offices and hospitals. We took these real-life lipid profiles and data on the kind/dose of used statins to estimate how treatment escalation such as changing statin treatment to a high dose (atorvastatin ≥40mg / rosuvastatin≥20mg), adding ezetimibe and adding a PCSK9-inhibitor might help to bring LDL-C-levels to the recommended Results A total of 7,865 patients were enrolled into DYSIS II, 6,794 had CCS and 1,071 ACS. Under the documented statin treatment in DYSIS only 12.7% of patients reached an LDL-C Conclusion Our analysis indicates that in real life practice the use available lipid-lowering medications would substantially increase the percentage of CCS- and ACS-patients reaching the newly recommended 2019 ESC guideline LDL-C-target of Funding Acknowledgement Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): MSD |
| تدمد: | 1522-9645 0195-668X |
| DOI: | 10.1093/ehjci/ehaa946.1445 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::887c58de26a27982b335975e2d76eea3 https://doi.org/10.1093/ehjci/ehaa946.1445 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........887c58de26a27982b335975e2d76eea3 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15229645 0195668X |
|---|---|
| DOI: | 10.1093/ehjci/ehaa946.1445 |